The serotonin receptor subtype 5-HT1A was one of the first serotonin receptor subtypes pharmacologically characterized. This receptor subtype has long been object of intense research and is implicated in the pathogenesis and treatment of anxiety and depressive disorders. In recent years, new chemical entities targeting the 5-HT1A receptor (alone or in combination with other molecular targets) have been proposed for novel therapeutic uses in neuroprotection, cognitive impairment, Parkinson’s disease, pain treatment, malignant carcinoid syndrome, and prostate cancer. This Perspective compares existing data on expression and signaling activity of the 5-HT1A receptor to a ligand with an intrinsic agonist or antagonist profile. Our purpose is also to make a complete overview, useful for underlining the features needed to select a specific pharmacological profile rather than another one. This aspect could be really interesting to consider and justify the 5-HT1A receptor as a new attractive target for drug discovery.

5‑HT1A Receptor: An Old Target as a New Attractive Tool in Drug Discovery from Central Nervous System to Cancer / Fiorino, Ferdinando; Severino, Beatrice; Magli, Elisa; Ciano, Antonio; Caliendo, Giuseppe; Santagada, Vincenzo; Frecentese, Francesco; Perissutti, Elisa. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 1520-4804. - 57:11(2014), pp. 4407-4426. [10.1021/jm400533t]

5‑HT1A Receptor: An Old Target as a New Attractive Tool in Drug Discovery from Central Nervous System to Cancer

FIORINO, FERDINANDO;SEVERINO, BEATRICE;MAGLI, ELISA;CIANO, ANTONIO;CALIENDO, GIUSEPPE;SANTAGADA, VINCENZO;FRECENTESE, FRANCESCO;PERISSUTTI, ELISA
2014

Abstract

The serotonin receptor subtype 5-HT1A was one of the first serotonin receptor subtypes pharmacologically characterized. This receptor subtype has long been object of intense research and is implicated in the pathogenesis and treatment of anxiety and depressive disorders. In recent years, new chemical entities targeting the 5-HT1A receptor (alone or in combination with other molecular targets) have been proposed for novel therapeutic uses in neuroprotection, cognitive impairment, Parkinson’s disease, pain treatment, malignant carcinoid syndrome, and prostate cancer. This Perspective compares existing data on expression and signaling activity of the 5-HT1A receptor to a ligand with an intrinsic agonist or antagonist profile. Our purpose is also to make a complete overview, useful for underlining the features needed to select a specific pharmacological profile rather than another one. This aspect could be really interesting to consider and justify the 5-HT1A receptor as a new attractive target for drug discovery.
2014
5‑HT1A Receptor: An Old Target as a New Attractive Tool in Drug Discovery from Central Nervous System to Cancer / Fiorino, Ferdinando; Severino, Beatrice; Magli, Elisa; Ciano, Antonio; Caliendo, Giuseppe; Santagada, Vincenzo; Frecentese, Francesco; Perissutti, Elisa. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 1520-4804. - 57:11(2014), pp. 4407-4426. [10.1021/jm400533t]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/576306
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 76
  • ???jsp.display-item.citation.isi??? 77
social impact